|
Economic aspects of nivolumab in non-small cell lung cancer (NSCLC): Lessons from real life. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Teva |
Honoraria - Pfizer; Roche |
Patents, Royalties, Other Intellectual Property - Interferon patents, approved |
Travel, Accommodations, Expenses - Roche |
|
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche/Genentech |
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); MSD (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly; Novartis |
Research Funding - Bristol-Myers Squibb (Inst) |
Other Relationship - Lilly; MSD; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |